Strategic approaches to developing drug treatments for ALS

被引：22

作者：

Vincent, Andrea M. ^{[1
]}

Sakowski, Stacey A. ^{[1
]}

Schuyler, Adam ^{[1
]}

Feldman, Eva L. ^{[1
]}

机构：

[1] Univ Michigan, Dept Neurol, Ann Arbor, MI 48109 USA

来源：

DRUG DISCOVERY TODAY | 2008年 / 13卷 / 1-2期

关键词：

D O I：

10.1016/j.drudis.2007.10.011

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Significant progress in understanding the cellular mechanisms of motor neuron degeneration in amyotrophic lateral sclerosis (ALS) has not been matched with the development of therapeutic strategies to prevent disease progression. The multiple potential causes and relative rarity of the disease are two significant factors that make drug development and assessment in clinical trials extremely difficult. We review recent progress in promoting therapeutics into clinical trials and highlight the value of moderate throughput screening for the acceleration and improvement of drug design.

引用

页码：67 / 72

页数：6

共 50 条

[1] Strategic Approaches to Creating and Developing the Concept of Business Integrity
Drakulevski, Ljubomir
Nakov, Leonid
[J]. STRATEGIC MANAGEMENT, 2016, 21 (02): : 23 - 31
[2] Two approaches to drug discovery in SODI-mediated ALS
Broom, Wendy J.
Auwarter, Kristen E.
Ni, Jake
Russel, Deborah E.
Yeh, Li-An
Maxwell, Michele M.
Glicksman, Marcie
Kazantsev, Aleksey G.
Brown, Robert H., Jr.
[J]. JOURNAL OF BIOMOLECULAR SCREENING, 2006, 11 (07) : 729 - 735
[3] Proteomics Approaches for Biomarker and Drug Target Discovery in ALS and FTD
Hedl, Thomas J.
San Gil, Rebecca
Cheng, Flora
Rayner, Stephanie L.
Davidson, Jennilee M.
De Luca, Alana
Villalva, Maria D.
Ecroyd, Heath
Walker, Adam K.
Lee, Albert
[J]. FRONTIERS IN NEUROSCIENCE, 2019, 13
[4] Strategic approaches for developing alternative tests for safety and potency of vaccines
Horiuchi, Yoshinobu
Ochiai, Masaki
Kataoka, Michiyo
Yamamoto, Akihiko
Yuen, Chun-Ting
Asokanathan, Cathy
Corbel, Michael
Kurata, Takeshi
Xing, Dorothy
[J]. INTERNATIONAL WORKSHOP ON ALTERNATIVE METHODS TO REDUCE, REFINE, AND REPLACE THE USE OF ANIMALS IN VACCINE POTENCY AND SAFETY TESTING: STATE OF THE SCIENCE AND FUTURE DIRECTIONS, 2011, 5 : 156 - 163
[5] Developing AMPA receptor aptamers as new drug candidates for ALS
Niu, L.
[J]. NEUROMUSCULAR DISORDERS, 2010, 20 (9-10) : 652 - 653
[6] Developing AMPA receptor aptamers as new drug candidates for ALS
Niu, L.
[J]. NEUROMUSCULAR DISORDERS, 2011, 21 (9-10) : 721 - 721
[7] Moving from products to solutions: Strategic approaches for developing capabilities
Paiola, Marco
Saccani, Nicola
Perona, Marco
Gebauer, Heiko
[J]. EUROPEAN MANAGEMENT JOURNAL, 2013, 31 (04) : 390 - 409
[8] Drug treatments and interactions, disease progression and quality of life in ALS patients
Diamanti, Luca
Bianchi, Elisa
Mucaj, Klodjana
Cereda, Cristina
Garattini, Silvio
Beghi, Ettore
Pupillo, Elisabetta
[J]. AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION, 2022, 23 (5-6) : 415 - 423
[9] Developing New Drug Treatments in the Era of Network Medicine
Silverman, E. K.
Loscalzo, J.
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 (01) : 26 - 28
[10] New Evidence Raises Hope for Developing Treatments and Approaches for Schizophrenia
不详
[J]. JOURNAL OF PSYCHOSOCIAL NURSING AND MENTAL HEALTH SERVICES, 2016, 54 (06) : 16 - 17

← 1 2 3 4 5 →